Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9037991 | 0.99 | SIGMAR1 (0.39) | SLC6A9OPRM1SLC6A5KCNH2SIGMAR1 | |
| SCHEMBL5556604 | 0.86 | SLC6A3 (0.39) | SLC6A9OPRM1DRD2 | |
| SCHEMBL8809000 | 0.86 | SLC6A9 (0.40) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL9037246 | 0.78 | SIGMAR1 (0.40) | SLC6A9OPRM1SLC6A5KCNH2SIGMAR1 | |
| SCHEMBL7948840 | 0.76 | SLC6A9 (0.33) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL8192173 | 0.74 | SIGMAR1 (0.37) | SLC6A9OPRM1SLC6A5KCNH2SIGMAR1 | |
| SCHEMBL20656301 | 0.72 | — | — | |
| SCHEMBL1138335 | 0.70 | SLC6A9 (0.56) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL15568523 | 0.70 | TAAR1 (0.41) | OPRM1SIGMAR1DRD2HSD17B10 | |
| SCHEMBL17135722 | 0.70 | OPRM1 (0.44) | OPRM1SIGMAR1DRD2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628978-A2 | TRIAZA-SPIRO COMPOUNDS AS NOCICEPTIN ANALOGUES AND USES THEREOF | Zealand Pharma A/S (DK) | 2006-03-01 | — | — | EP | claimed |
| EP-1537110-A4 | TRIAZOSPIRO COMPOUNDS HAVING NOCICEPTIN RECEPTOR AFFINITY | EURO CELTIQUE SA (LU) | 2005-06-08 | — | — | EP | claimed |
| EP-1537110-A2 | TRIAZOSPIRO COMPOUNDS HAVING NOCICEPTIN RECEPTOR AFFINITY | Euro-Celtique, S.A. (LU) | 2005-06-08 | — | — | EP | claimed |
| WO-2004104004-A2 | TRIAZA-SPIRO COMPOUNDS AS NOCICEPTIN ANALOGUES AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2004-12-02 | — | — | WO | claimed |
| WO-2001039723-A2 | TRIAZOSPIRO COMPOUNDS HAVING NOCICEPTIN RECEPTOR AFFINITY | EURO-CELTIQUE, S.A. (LU) | 2001-06-07 | — | — | WO | claimed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | ON TARGET THERAPEUTICS LLC | 2019-05-09 | — | — | US | disclosed |
| US-8206593-B2 | Adapted for on-chip solvent exchange; synthesis of radiopharmaceuticals such as FDG (fludeoxyglucose F18) for example | FLUIDIGM CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1720874-A1 | 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Bioaxone Therapeutique Inc. (CA) | 2006-11-15 | — | — | EP | disclosed |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-19 | — | — | US | disclosed |
| WO-2002083673-A1 | 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2001094346-A1 | 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-13 | — | — | WO | disclosed |
| US-6172073-B1 | BENZIMIDAZOLYLOXY ALKANAMINES AS SEROTONIN REUPTAKE INHIBITORS; NICOTINE AND TOBACCO WITHDRAWAL; PSYCHOLOGICAL, EATING, BRAIN, GASTROINTESTINAL, SLEEP, AND SEXUAL DISORDERS | ELI LILLY AND COMPANY | 2001-01-09 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0696280-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0273168-A1 | Triazaspirodecanylmethylindolone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | SLC6A9 4573/4885OPRM1 1737/4885SLC6A5 4591/4885 |
| US-20020193599-A1 | Dihydropyridines and new uses thereof | BPHL, BCKDK, DHCR7 | SLC6A9 3491/4885OPRM1 311/4885SLC6A5 3245/4885 |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | LDLR, HDLBP, LIPG | SLC6A9 4573/4885OPRM1 1737/4885SLC6A5 4591/4885 |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | SLC6A9 733/4885OPRM1 264/4885SLC6A5 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.